Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cathinone is a naturally occurring monoamine alkaloid found in the leaves of the *Catha edulis* (khat) shrub. It is structurally related to amphetamines and is considered the primary psychoactive component responsible for the stimulant effects of khat. Cathinone acts as a norepinephrine–dopamine releasing agent (NDRA), stimulating the release of dopamine and inhibiting reuptake of epinephrine, norepinephrine, and serotonin in the central nervous system. This leads to increased alertness, euphoria, talkativeness, and other stimulant effects similar to those produced by amphetamines[3][7][8]. The drug can also cause adverse cardiovascular and neurological effects at higher doses or with chronic use[5]. Internationally, cathinone is classified as a Schedule I controlled substance due to its potential for abuse[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cathinone.